Mycophenolate Mofetil Accord Healthcare Ireland (Mycophenolate Mofetil)

After oral administration, Mycophenolate Mofetil is converted to mycophenolic acid, which blocks the enzyme inosine monophosphate dehydrogenase (IMPDH). This inhibition stops the synthesis of guanosine nucleotides needed for lymphocyte proliferation, thereby dampening the immune response.

The exact dose of Mycophenolate Mofetil is individualized by the prescribing clinician based on the patient’s condition, weight, renal function, and other medications. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Mycophenolate Mofetil is classified as pregnancy category D, indicating evidence of fetal risk. It should only be used during pregnancy when the potential benefit justifies the risk, and breastfeeding is generally not recommended because the drug is excreted in milk. Discuss alternatives with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs), and the necessary import documentation.

Compared with calcineurin inhibitors (e.g., cyclosporine) or azathioprine, Mycophenolate Mofetil offers a different mechanism—targeting nucleotide synthesis rather than calcineurin signaling. It often provides a favorable side‑effect profile regarding nephrotoxicity but may cause more gastrointestinal upset and bone‑marrow suppression, requiring regular monitoring.

Store the product at temperatures below 25 °C, in its original packaging, and protect it from moisture and direct sunlight. Do not refrigerate or freeze the tablets. Keep out of reach of children and dispose of any unused material according to local regulations.

Mycophenolate Mofetil is taken orally, usually with food or a light snack to lessen gastrointestinal irritation. The tablets should be swallowed whole with a full glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

Serious adverse events include severe leukopenia or neutropenia, which can lead to life‑threatening infections, hepatic toxicity, and rare opportunistic infections such as progressive multifocal leukoencephalopathy (PML). Patients should report signs of infection, unusual bruising, or jaundice promptly.

Mycophenolate Mofetil is contraindicated in patients with known hypersensitivity to the drug, those who are pregnant unless the benefits outweigh the risks, and individuals with severe uncontrolled infections. Caution is also advised for patients with significant renal or hepatic impairment.